28 March 2026
Lilly: Taltz + Zepbound superior to Taltz alone in psoriatic arthritis with obesity
Phase 3b TOGETHER‑PsA: combination therapy improved ACR50, MDA, fatigue, function, QoL and cardiometabolic markers; 36‑week primary endpoint met (ACR50+≥10% weight loss 31.7% vs 0.8%).
